Immunic, Inc. (NASDAQ: IMUX)

Immunic, Inc. (IMUX) is a biotechnology company that operates in the field of developing clinical pipelines of selective oral immunology therapies, primarily focusing on treating chronic inflammatory and autoimmune diseases. Headquartered in New York City, with its main operations based in Gräfelfing near Munich, Germany, Immunic has a team of experienced professionals who specialize in drug discovery, product development, chemistry, manufacturing, and controls processes, intellectual property, clinical trial design, health economics, and market access.

Immunic's primary business activities revolve around developing orally administered, small molecule programs that target specific inflammatory and autoimmune diseases. The company's product candidates include vidofludimus calcium (IMU-838), IMU-856, and IMU-381. Vidofludimus calcium is an investigational drug in development as a next-generation treatment option for patients with multiple sclerosis (MS) and other chronic inflammatory and autoimmune diseases. The drug has shown therapeutic activity in Phase 2 clinical trials in patients with relapsing-remitting MS and progressive MS and has also shown anti-inflammatory and antiviral effects. IMU-856, on the other hand, is an orally available and systemically acting small molecule modulator that targets Sirtuin 6 (SIRT6), a protein that serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium, representing a unique treatment approach for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, short bowel syndrome, and irritable bowel syndrome with diarrhea. IMU-381 is a next-generation molecule with improved overall properties, supported by a series of chemical derivatives, and is currently in preclinical testing for the treatment of gastrointestinal diseases.

Immunic has a strong competitive position in the industry, with a unique combination of small molecule programs and a strong scientific foundation. The company's product candidates have shown promising results in clinical trials, and Immunic is well-positioned to continue to advance its pipeline of products. Immunic's customers include patients with chronic inflammatory and autoimmune diseases, as well as healthcare providers and payers. The company's products are designed to provide a new treatment option for patients with these diseases, and Immunic is working to establish itself as a leader in the development of oral immunology therapies.

Immunic's main brands include vidofludimus calcium (IMU-838), IMU-856, and IMU-381, all of which are currently in various stages of clinical trials. The company's financial condition is uncertain, with the company having incurred operating losses in each year since its inception and having an accumulated deficit of approximately $410.9 million as of December 31, 2023. However, Immunic has raised net cash of approximately $431.4 million from private and public offerings of preferred and common stock and has cash and cash equivalents of approximately $46.7 million as of December 31, 2023.